Immune Checkpoint Inhibitor Clinical Trials

41 clinical trials for Immune Checkpoint Inhibitor across international registries, including 15 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Granzyme B-PET: Predicting Immunotherapy Efficacy in TNBC — RECRUITING
• Intestinal Low-Dose Radiotherapy Plus Immunochemotherapy for Conversion of Borderline Resectable/Unresectable Esophageal Squamous Cell Carcinoma — RECRUITING · PHASE2
• Thymosin Alpha 1 Combined With Anti-PD-1 Monoclonal Antibody in Elderly Patients With Advanced Melanoma — RECRUITING · PHASE2
• IC Plus Low-dose Radiation Plus Cadonilimab in LANPC — RECRUITING · PHASE3
• Spatially Fractionated Radiotherapy Combined With Immunotherapy for Advanced Solid Tumors — RECRUITING · PHASE2
• Analysis of PD-L1, TMB, MSI and ctDNA Dynamics to Predict and Monitor Response to Immunotherapy in Metastatic Cancer. — RECRUITING
• Adjuvant Radiotherapy of Sintilimab Versus TACE for HCC — RECRUITING · PHASE3
• A Study of Multimodal Radiotherapy for Renal Cell Carcinoma Progressed After Prior Immunotherapy — RECRUITING · PHASE2
• Efficacy and Safety of Super-hyperfractionation Pulse Radiotherapy Combined With ICIs for Advanced NSCLC — RECRUITING · NA
• Liver Cancer and Immunotherapy in the Liquid Biopsy Era — RECRUITING · NA
• Safety Assessment of Concurrent Radiotherapy and Novel Systemic Therapy for Breast Cancer — RECRUITING · NA
• Toripalimab Plus FLOT in Locally Advanced Gastric Cancer — RECRUITING · PHASE2
• LAG3 Expression in Triple Negative Breast Cancer — RECRUITING · NA
• COVID-19 Vaccine Effectiveness Against Recurrent Infection Among Lung Cancer Patients and Biomarker Research — RECRUITING · NA
• Fast-Track Cardiovascular Assessment for Suspicion of Cardiovascular Events on Immunecheckpoint Inhibitors — RECRUITING
• A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer — COMPLETED · PHASE2
• Troponin to Detect Major Cardiovasculaire Advserse Events on Immune Checkpoint Inhibitors — COMPLETED
• Adjuvant Anti-PD-1 Therapy in Resected Hepatocellular Carcinoma — NOT_YET_RECRUITING
• PRaG-1 Plus PRaG Therapy in Advanced Solid Tumors: A Prospective Clinical Trial (PRaG 10.0) — NOT_YET_RECRUITING · PHASE2
• Study on the Relationship Between Opioid Drugs and the Therapeutic Efficacy of Immunotherapy — NOT_YET_RECRUITING
• Neoadjuvant/Adjuvant Pembrolizumab Plus Chemotherapy — ACTIVE_NOT_RECRUITING · PHASE2
• Exploratory Study on the Therapeutic Effect Prediction Model of Advanced BTC Immunotherapy — OTHER · PHASE1
• Adjuvant Tislelizumab Plus Lenvatinib for Patients at High-risk of HCC Recurrence After Curative Resection or Ablation — OTHER · PHASE3
• Safety and Efficacy of RX-af01 Combined With PD-1 Antibody — OTHER · PHASE1
• A Prospective Study of Pembrolizumab Combining Chemotherapy in Advanced NSCLC Patients With EGFR Exon 21 Point Mutation. — NOT_YET_RECRUITING · PHASE2
• Study to Evaluate Efficacy and Safety of Selective Internal Radiation Therapy Plus Xelox, Bevacizumab and Atezolizumab (Immune Chekpoint Inhibitor) in Patients With Liver-dominant Metastatic Colorectal Cancer — OTHER · PHASE2
• Sintilimab Combined With Modified FLOT Regimen in the Treatment of Metastatic Gastric Cancer — OTHER · PHASE2
• Clinical Significance of Hepatic Biomarkers in Lung Cancer Patients Treated With Immune Checkpoint Inhibitors — WITHDRAWN · NA
• Stereotactic Body Radiotherapy Combined With Cadonilimab for Advanced Refractory Malignant Solid Tumors — OTHER · PHASE1
• Correlation Between Pre-transplant ICI Exposure and Post-transplant Graft Rejection — OTHER
• Tislelizumab Combing Chemoradiotherapy in Recurrent Cervical Cancer — OTHER
• A Pilot Study to Understand the Impact of Therapy With Tumour Treating Fields (TTFields) in NSCLC — NOT_YET_RECRUITING · NA
• Immune Checkpoint Inhibitors(ICPis)-Induced Endocrine Immune-related Adverse Events (irAEs) — COMPLETED
• Development of an EORTC Immune Checkpoint Inhibitor-specific Quality of Life Item List: Phase 1 & 2 — OTHER
• Clinical Observation of ICI Combined With Recombinant Human Endostatin on Leptomeningeal Metastasis of Lung Cancer — OTHER · PHASE2
• PD-1 Antibody Plus Chemoradiotherapy for IB2-IIIB Cervical Cancer — OTHER · PHASE2
• Toripalimab Based Induction Chemotherapy Followed by De-escalation Protocols in HPV-related OPSCC — OTHER · NA
• Immune Checkpoint Inhibitors and Radiotherapy in Relapsed/Refractory Hodgkin Lymphoma — OTHER
• Cardiac Adverse Reactions Related to Immune Checkpoint Inhibitor in NSCLC Patients — OTHER
• Thyroid Dysfunction and Nivolumab Reponse in NSCLC — COMPLETED
• Anti-PD-1 Antibody Combined With Peg-Asparaginase and Chidamide for the Early Stage of NK/T Cell Lymphoma — OTHER · PHASE2

Refine this search